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Abstract
OBJECTIVE: To investigate the inhibitory effect of
Yiguanjian decoction (YD) on DNA damage in Con-
canavalin A (Con A)-induced liver injury mice mod-
el and to explain the possible mechanism.
METHODS: Totally 120 male BALB/c mice were ran-
domly divided into 6 groups, 20 mice each: normal
group, model group, Bifendate group, YD low dose
group, YD middle dose group and YD high dose
group. Except normal group, liver injury model in-
duced by Con A was established. While modeling,
each mouse in YD group was given YD (0.4 mL/20 g
per day) by intragastric administration (0.13 g YD
for YD low dose group; 0.26 g for YD middle dose
group; 0.52 g for YD high dose group). Bifendate
group was given Bifendate (0.2 g·kg-1·d-1) by ga-
vage. Normal group and model group were fed
with same volume of physiological saline daily. Af-
ter 8 weeks, the serum alanine transaminase (ALT)
and aspartate transaminase (AST) were tested. The
hematoxylin-eosin staining was used to evaluate
the grade of liver inflammation and liver fibrosis
stage. Hepatocellular DNA damage was detected
by single cell gel electrophoresis technology. The
protein expression of tumor necrosis factor-α
(TNF-α), Bax and MutT Homolog 1 (MTH1) was de-
tected by western blotting and enzyme linked im-
munosorbent assay. Bax mRNA and MTH1 mRNA
were detected by Real-time Polymerase Chain Reac-
tion (PCR).
RESULTS: YD can improve the degree of liver in-
flammation and fibrosis in the liver of chronic hepa-
titis mice, the dose effect relationship is remarkable
(P < 0.05). YD can reduce liver cell DNA damage.
The difference between YD middle dose group and
model group was statistically significant (P < 0.05).
YD middle dose group had decreased the protein
expression of TNF-α in the mice liver of immunolog-
ical liver injury (P < 0.05). YD can increase the pro-
tein expression of Bax (P < 0.05). Compared with
normal group, the protein expression of MTH1 was
decreased (P < 0.05), but there was no statistical sig-
nificance between YD group and model group (P >
0.05). YD can increase the mRNA expression of Bax
and MTH1 (both P < 0.05).
CONCLUSION: YD can effectively inhibit the DNA
damage in immunological liver injury mice, the
mechanism may be that it can decrease the TNF-α
and increase the Bax and MTH1 expression.
Key words: Drug-induced liver injury; Liver kidney
Yin deficiency; DNA damage; Concanavalin A;
Yiguanjian decoction
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INTRODUCTION
China is a high incidence area of hepatitis B virus
(HBV) infection, liver cirrhosis and hepatocellular can-
cer (HCC) are the leading causes of death in the
crowd. About 110 000 people died from HCC each
year in China, which accounted for 45% of deaths
worldwide. And about 90 percent of liver cancer pa-
tients were infected with HBV.1 Therefore, the key mea-
sure to reduce the incidence of HCC is active treat-
ment of chronic hepatitis B (CHB), which can prevent
CHB developing into cirrhosis or HCC.
The mechanism of CHB leading into HCC has not
been fully elucidated, but it is closely associated with
the accumulation of DNA damage. HBV can not only
cause liver cell DNA damage, but also can directly or
indirectly affect the repair system, then block DNA re-
pair and eventually lead to liver cancer.2-4 How to inhib-
it DNA damage and promote the repair of it is the
main measure, but there is no such drugs in clinical,5-7
we need further study.
One study found that the active ingredients of Tradi-
tional Chinese Medicine (TCM) Tanshinone has some
antagonistic action on the DNA damage in peripheral
blood lymphocytes of CHB patients induced by H2O2.8
Another study found that grape seed proanthocyani-
dins (GSP) can antagonize CdCl2-induced hepatic oxi-
dative damage and may inhibit DNA damage or pro-
mote DNA repair in rats.9 Since the pathology of
chronic hepatitis B is mainly immunological liver inju-
ry, to study TCM on whether it can inhibit or repair
the DNA damage in liver cell immune injury is neces-
sary for founding effective medicine to treat HBV pa-
tients.
TCM treatment of CHB has achieved remarkable re-
sults.6 Epidemiological findings show that Yin deficien-
cy syndrome of liver and kidney is a common but im-
portant syndrome of CHB.10,11 Yiguanjian decoction
(YD) is a famous prescription which has the function
of nourishing Yin and dispersing stagnated liver Qi.
Clinical practice has proved YD does have good effica-
cy on treatment of Yin deficiency syndrome of liver
and kidney of CHB.12 Experimental studies have found
the anti-inflammatory effect of YD is related to its inhi-
bition of hepatic apoptosis.13 DNA damage is the basis
for conversion of hepatitis to HCC but there is no re-
search to indicate whether YD can inhibit and repair
DNA damage of liver cells. We choose immunological
liver injury in mice as the experimental animal model,
to observe the inhibitory effects of YD on DNA dam-
age of Con A-induced immune liver injury, and to ex-
plore its molecular mechanism.
MATERIALS ANDMETHODS
Animals
Totally 120 healthy male BALB/c mice of specific
pathogen free (SPF) grade, six-month-old, weighing
(20 ± 2) g, were acquired from Vital River Laboratories
Animal Technology Co., Ltd. (Certificate of quality
No. SCXK [Beijing] 2012-0001, Beijing, China). Mice
were housed in the SPF level animal laboratory in De-
partment of Laboratory Animal Science of Capital
Medical University, maintained at constant tempera-
ture (22-24)℃ and humidity (30%-45%) under a 12 h
light/dark cycle, and all mice had free access to food
and water. All experiments were approved by the Exper-
imental Animal Ethics Committee of Capital Medical
University.
Drugs
YD consists of Beishashen (Radix Glehniae) 9 g, Maid-
ong (Radix Ophiopogonis Japonici) 9 g, Danggui (Radix
Angelicae Sinensis) 9 g, Dihuang (Radix Rehmanniae)
20 g, Gouqizi (Fructus Lycii) 12 g, Chuanlianzi (Fruc-
tus Toosendan) 4.5 g. All components were purchased
from the Beijing Tongrentang Drugstore(Beijing, Chi-
na). The aqueous extract of YD was prepared accord-
ing to the following procedures: These herbs were
soaked in 6 times (v/w) distilled water for an hour and
then heated to boiling and decocted for 30 min. The
filtrate was then collected. The residue was decocted
for 20 min with 4 times (v/w) distilled water, and then
the filtrate was collected and mixed with the previously
collected filtrate. YD was made at a high dose (1.3 g/
mL) and a middle dose (0.65 g/mL) and a low dose
(0.33 g/mL) and stored at 4 ℃ until use. Bifendate
Pills made by Beijing Union Pharmaceutical Factory
(Beijing, China), were powdered and dissolved in de-
ionized water at a concentration of 10 mg/mL. Con A
made by Sigma-Aldrich Co. LLC. (St. Louis, MO,
USA) was dissolved in deionized water at a concentra-
tion of 2 mg/mL.
Reagents
RNAprep pure Tissue Kit and Fast Quant RT kit
(With gDNase) were purchased from TIANGEN Bio-
tech (Beijing) Co., Ltd. (Beijing, China). SYBR Premix
Ex Taq (Tli RNaseH Plus) was purchased from Takara
Biotechnology (Dalian) Co., Ltd. (Dalian, China).
Mouse tumor necrosis factor-α (TNF-α) enzyme
linked immunosorbent assay (ELISA) Kit was pur-
chased from eBioscience, Inc. (San Diego, CA, USA).
Anti-Bax and Anti-MutT Homolog 1 (MTH1) anti-
body were purchased from Abcam Trading Company
Ltd. (Cambridge, MA, USA). Anti-TNF-α and an-
ti-β-actin antibodies were purchased from Cell Signal-
ing Technology, Inc. (Danvers, MA, USA). Dylight
680 AffiniPure Goat anti-rabbit IgG and Dylight 800
AffiniPure Goat anti-Mouse IgG were purchased from
EarthOx Life Sciences (Millbrae, CA, USA). RIPA Ly-
sis Buffer and protease inhibitors and bicinchoninic ac-
id (BCA) protein concentration assay kit were pur-
chased from Beijing DINOAO Biological Technology
Co., Ltd. (Beijing, China).
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Instruments
Instruments used included: Model 680 Microplate
Reader and PowerPac ™ Universal power supply and
Mini-PROTEAN Tetra cell and Mini Trans-Blot cell
(BIO-RAD Laboratories Ltd., Hercules, CA, USA),
high speed desktop refrigerated centrifuge (Heraeus
Ltd., Hanau, Germany), Applied Biosystems 7300
Real-Time PCR machine (Applied Biosystems, Inc.,
Carlsbad, CA, USA), and LI-COR Odyssey Infrared
Imaging System (LI-COR, Inc., Lincoln, NE, USA).
Grouping and treatment
The animals were conveniently fed for one week and
were randomly divided into six groups (n = 20 per
group) by the random number table method: normal
group (A), model group (B), Bifendate group (C), YD
low dose group (D), YD middle dose group (E) and
YD high dose group (F).
Mice in the normal group were intraperitoneally inject-
ed with physiological saline (0.1 mL/10 g body weight)
once a week for eight weeks, while other groups were
intraperitoneally injected with Con A (0.1 mL/10 g
body weight). While modeling, each mouse in YD
group was given YD (0.4 mL/20 g body weight/day)
by intragastric administration (0.13 g YD for YD low
dose group; 0.26 g for YD middle dose group; 0.52 g
for YD high dose group). Bifendate group was given Bi-
fendate (0.2 g·kg-1·d-1) by intragastric administration.
The normal group and model group were fed with
same volume of physiological saline daily. The adminis-
tration dose of the mouse was calculated according to
the equivalent body surface area method and was ad-
justed according to the change of weight.
Collection of samples
All mice were anaesthetized by intraperitoneal injec-
tion of 5% chloral hydrate (5 mL/kg) on the eighth
weekend. Blood samples were drawn from the eye
ground venous plexus, centrifuged at 3000 rpm for
15 min at 4 ℃ after an hour to separate the serum,
and then the serum was kept at －80 ℃ for liver func-
tion tests. A small piece of liver tissue was fixed in 10%
formaldehyde and embedded in paraffin. The remain-
ing liver tissue was immediately placed in liquid nitro-
gen and stored at－80℃ before use.
Liver function tests
SXOUT Ⅱ semi-automatic biochemical analyzer was
used to determine the content of serum alanine trans-
aminase (ALT) and aspartate transaminase (AST).
Histopathological examination
Paraffin-embedded tissue sections were stained with he-
matoxylin-eosin (HE), and the grade of liver inflamma-
tion (G) and liver fibrosis stage (S) in mice were
judged by the same pathologist according to the Na-
tional criteria 2000 revision (Table 1).14
Single cell gel electrophoresis assay (SCGE) (Comet
Assay) for detecting hepatocellular DNA damage
The SCGE was carried out by the method described
by Speit and Hartmann.15 20 μL cell suspension was
mixed with 70 μL 0.7% low melting point agarose and
then placed on frosted slides that were pregelatinized
with 1% normal melting point agarose. The slides were
covered with cover glass and kept refrigerated at 4 ℃ to
solidify the gel. The slides were then immersed in
chilled lysis solution (2.5 M NaCl, 100 mM
Na2EDTA, 10 mM Tris-HCl pH 10, 1% Triton X-100
and 10% DMSO) in the dark at 4 ℃ for 1.5 h. And
then the slides were placed in an electrophoresis cham-
ber, covered with electrophoresis buffer at 4 ℃ for
20 min without light. The electrophoresis ran at 300 mA
and 25V for the next 20 min. The slides were then neu-
tralized with 0.4 M Tris-HCl buffer, pH 7.5 for three
times (5 min each time). After being stained with 50 μL
of ethidium bromide (2 μg/mL), the sides were exam-
ined with a fluorescence microscope (excitation filter of
515-560 nm and barrier filter of 590 nm) at 400× mag-
nification. Image analysis was performed using the
Comet Assay Software Project on 100 randomly select-
ed and non-overlapping cells. Olive tail moment
[OTM, (tail mean－ head mean]× [tail DNA content/
total DNA content × 100% )] was used to evaluate
DNA damage of the cells.
Western blotting for detecting the protein expression
of TNF-α, Bax and MTH1
Liver tissue (50-100 mg) was mixed with 0.5 mL RIPA
lysis buffer and 5 μL protease inhibitors and then the
total protein was extracted after homogenized and cen-
trifuged. Protein concentrations were determined by a
Table 1 Scoring criteria of liver inflammation grade and liver fibrosis stage
Score
0
1
2
3
4
Liver inflammation grade
Inflammation of the portal area
Non-existent
A few inflammatory cells infiltration
Massive inflammatory cells infiltration
Moderate amounts of piecemeal necrosis
Severe piecemeal necrosis
Inflammation in hepatic lobule
Non-existent
Degeneration and few spotty necrosis
Degeneration and spotty necrosis
Large necrosis area
Large patchy necrosis
Liver fibrosis stage
Degree of hepatic fibrosis
Non-existent
Periportal fibrosis and localized
perisinusoidal fibrosis
Fibrosis around portal area and fibrous
septums
Fibrous septums and lobule structural
disorder
Early cirrhosis
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BCA protein concentration assay kit. Equal amounts
(50 μg) of protein in each sample were separated by
SDS-polyacrylamide gel electrophoresis and then trans-
ferred onto a NC membrane. After being blocked with
5% skim milk in Tris buffered saline tween for 1 h, the
membrane was incubated overnight with the primary
antibody at 4 ℃ , then incubated with the secondary
antibody for 1 h at room temperature. The protein
bands were scanned on an Odyssey infrared fluorescent
scanner (LI-COR) and analyzed with Odyssey software
version 2.0. The results were compared with the densi-
tometric signal of β-actin and the ratios were expressed
as the relative protein contents.
Real-time PCR for detecting the mRNA expression of
Bax and MTH1
Total RNA was extracted from liver tissue specimens
by using the RNAprep pure Tissue Kit and reverse tran-
scribed into cDNA by using the FastQuant RT kit
(With gDNase) according to the manufacturer's guide-
lines. The expression of β-actin was used as an internal
control.
The primers used for RT-PCR are as follows:
Bax forward primer: 5'-GAACAGATCATGAAGA-
CAGGG-3'
Bax reverse primer: 5'-CAGTTCATCTCCAATTC-
GCC-3'
MTH1 forward primer: 5'-CCTGTTTTAGAAGG-
TTGTGGCA-3'
MTH1 reverse primer: 5'-GTGTGAGCAGACAGTA-
AGCGGT-3'β-actin forward primer: 5'-GGCTGTATTCCCCTC-
CATCG-3'β-actin reverse primer: 5'-CCAGTTGGTAACAAT-
GCCATGT-3'
PCR reaction conditions were as follows: initial dena-
turation was performed at 95 ℃ for 30 s, followed by
40 cycles of denaturing at 95 ℃ for 5 s and extension
at 60℃ for 30 s. To verify the specificity of the amplifi-
cation reaction, a melting curve analysis was per-
formed. The relative transcript amount of the target
gene was normalized to that of β-actin by using the
2−ΔΔCt method.
ELISA for detecting the protein expression of TNF-α
The frozen liver tissues were homogenized in cold PBS.
The homogenate was centrifuged at 1000 rpm for 5 min
and then the supernatants were collected. The amount
of TNF-α in liver tissue was quantified according to
the manufacturer's instructions.
Statistical analysis
Data were expressed as mean ± standard deviation ( xˉ
± s). Statistical analysis was performed using SPSS 13.0
(SPSS Inc., Chicago, IL, USA). Differences among
groups were compared by analysis of variance, compari-
son between samples was compared by multiple com-
parisons: least significant difference method. The χ2
test was used for enumerated data. P value < 0.05 was
considered statistically significant.
RESULTS
Liver function tests
Compared with normal group, the content of serum
ALT and AST in model group increased significantly
(both P < 0.05), indicating that the animal model was
established successfully. The results showed that the
ALT and AST levels were significantly decreased in the
Bifendate group, YD low dose group, YD middle dose
group and YD high dose group compared with model
group (all P < 0.05). The results suggest that YD can
improve the liver function and middle-dose YD has a
better effect in protecting liver (Table 2).
Changes in histopathology
The study found that in the normal group, hepatic lob-
ule had a normal structure; cell cords were arranged
radically; hepatic sinusoid and central vein were clear.
The structure of liver cells in the model group could be
recognized, but great necrosis foci was also observed,
accompanied by a large amount of inflammatory cell
infiltration and fibrous tissue proliferation. The degree
of liver inflammation and fibrosis between normal
group and model group existed significant differences
(both P < 0.05). The pathohistological examination
showed that liver tissues in Bifendate group, YD low,
middle and high dose group were improved compared
with the model group: inflammatory cell infiltration
was reduced significantly; the structure of hepatic lob-
ule was normal and cell cords were arranged radically.
Inflammatory activity was decreased significantly in Bi-
fendate group, YD low dose, middle dose and high
dose group compared with the model group (all P <
0.05). The degree of liver fibrosis decreased significant-
ly in Bifendate group, YD low dose, middle dose and
high dose group compared with the model group (all
P < 0.05). The results indicated that the immune liver
injury mice model was established successfully. YD
could decrease the degree of liver fibrosis and inflam-
mation in mice with immune liver injury (Tables 3, 4;
Figure 1).
Group
Normal
Model
Bifendate
Low-dose YD
Middle-dose YD
High-dose YD
n
20
20
20
20
20
20
ALT (IU/L)
40.3±4.0
144.8±68.4a
38.0±9.1b
51.5±17.3
32.0±1.5b
43.9±7.2b
AST (IU/L)
110.6±8.7
193.7±46.2a
98.1±9.0b
103.9±13.8b
97.4±7.9b
131.2±17.3
Notes: the normal group and model group were given physiolog-
ical saline (0.4 mL/20 g body weight) daily for eight weeks. Bi-
fendate group was administered Bifendate (0.2 g/kg) by gavage.
The YD groups were given the corresponding concentration of
YD (0.4 mL/20 g body weight) by gavage. aP < 0.05, compared
with normal group; bP < 0.05, compared with model group.
ALT: alanine transaminase; AST: aspartate transaminase; YD:
Yiguanjian decoction.
Table 2 Comparison of liver function between groups ( xˉ ± s)
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Concentration-response relationship analysis
With the increase of drug concentration, the degree of
inflammation of the liver tissue was on the decline, the
rank correlation coefficient is － 0.708, P value is
0.000, there was statistical difference between groups.
With the increase of drug concentration, the degree of
liver fibrosis was on the decline, the rank correlation
coefficient is－0.648, P value is 0.000, there was statis-
tical difference between groups. The study suggests
that YD can improve the degree of liver inflammation
and fibrosis in the liver of chronic hepatitis mice, the
dose effect relationship is remarkable.
Hepatocellular DNA damage detected by SCGE assay
Compared with the normal group and YD middle dose
group, the OTM in model group increased significant-
ly (P < 0.05) (Figure 2, Table 5).
Protein expressions of TNF-α, Bax and MTH1
Western blotting showed that the expression of TNF-α
was markedly reduced by YD and Bifendate treatments
Table 3 Comparison of liver inflammation grade between groups
Group
Normal
Model
Bifendate
Low-dose YD
Middle-dose YD
High-dose YD
n
10
10
10
10
10
10
0
10
0
0
0
0
0
1
0
0
2
0
8
8
2
0
3
8
6
2
0
3
0
4
0
4
0
2
4
0
3
0
0
0
0
χ2 value
-
20.000
11.273
10.400
15.200
14.667
P value
-
0.000a
0.01b
0.006b
0.002b
0.002b
Notes: the normal group and model group were given physiological saline (0.4 mL/20 g body weight) daily for eight weeks. Bifendate
group was administered Bifendate (0.2 g/kg) by gavage. The YD groups were given the corresponding concentration of YD (0.4 mL/20 g
body weight) by gavage. aP < 0.05, compared with normal group; bP < 0.05, compared with model group. YD: Yiguanjian decoction.
Table 4 Comparison of liver fibrosis stage between groups
Group
Normal
Model
Bifendate
Low-dose YD
Middle-dose YD
High-dose YD
n
10
10
10
10
10
10
0
10
0
0
0
0
0
1
0
0
2
0
8
8
2
0
6
8
8
2
2
3
0
4
0
2
0
0
4
0
0
0
0
0
0
χ2 value
-
20.000
6.286
0.952
14.000
14.000
P value
-
0.000a
0.043b
0.329b
0.001b
0.001b
Notes: the normal group and model group were given physiological saline (0.4 mL/20 g body weight) daily for eight weeks. Bifendate
group was administered Bifendate (0.2 g/kg) by gavage. The YD groups were given the corresponding concentration of YD (0.4 mL/20 g
body weight) by gavage. aP < 0.05, compared with normal group; bP < 0.05, compared with model group. YD: Yiguanjian decoction.
Figure 1 Pathological changes in the groups (HE staining, × 200)
A: normal group; B: model group; C: bifendate group; D: YD low dose group; E: YD middle dose group; F: YD high dose group. The
normal group and model group were given physiological saline (0.4 mL/20 g body weight) daily for eight weeks. Bifendate group
was administered Bifendate (0.2 g/kg) by gavage. The YD groups were given the corresponding concentration of YD (0.4 mL/20 g
body weight) by gavage. YD: Yiguanjian decoction; HE: hematoxylin-eosin.
A B C
D E F
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(P < 0.05). Expressions of Bax and MTH1 in model
group were apparently decreased compared with nor-
mal group (both P < 0.05). The protein level of Bax in
YD middle dose group increased significantly versus
the model group (P < 0.05). Expression of MTH1 in
YD middle dose group was increased against the model
group but there was no significant difference (P >
0.05) (Figure 3, Table 6).
Comparison of mRNA for Bax and MTH1 by
RT-PCR
The mRNA expressions of Bax and MTH1 in model
group were significantly reduced compared with nor-
mal group (both P < 0.05). The mRNA expressions of
Bax and MTH1 in YD middle dose group had a signifi-
cant increase compared with model group (both P <
0.05) (Table 7).
Comparison of TNF-α by ELISA
The protein expressions of TNF-α in liver tissue exist-
ed significant difference between normal group and
model group (P < 0.05). Compared with model group,
TNF-α in YD middle dose group decreased significant-
ly (P < 0.05) (Table 8).
DISCUSSION
Con A-induced immunological liver injury mice mod-
Table 5 Comparison of liver cells OTM among groups ( xˉ ± s)
Group
Normal
Model
Bifendate
Low-dose YD
Middle-dose YD
High-dose YD
n
10
10
10
10
10
10
OTM
7.0±1.3
57.6±7.4a
19.0±4.0b
39.2±3.5
30.6±5.9b
26.7±3.5b
Notes: the normal group and model group were given normal sa-
line daily for eight weeks. Bifendate group was administered Bi-
fendate by gavage. The YD groups were given the corresponding
concentration of YD by gavage. aP < 0.05, compared with nor-
mal group; bP < 0.05, compared with model group. OTM: olive
tail moment; YD: Yiguanjian decoction.
1 2 3 4
Bax
TNF-α
MTH1
β-actin
kDa
21
18
23
40
Figure 3 Protein expression of Bax, TNF-α, MTH1 and β-actin
in groups
1: Normal group; 2: Model group; 3: Bifendate group; 4: YD
middle dose group. The normal group and model group
were given normal saline daily for eight weeks. Bifendate
group was administered Bifendate by gavage. The YD
groups were given the corresponding concentration of YD
by gavage. TNF-α: tumor necrosis factor-α; MTH1: MutT Ho-
molog 1; YD: Yiguanjian decoction.
Figure 2 Liver cells DNA comet image in the groups (Ethidium bromide staining, × 400)
A: normal group; B: model group; C: bifendate group; D: YD low dose group; E: YD middle dose group; F: YD high dose group. The
normal group and model group were given physiological saline (0.4 mL/20 g body weight) daily for eight weeks. Bifendate group
was administered Bifendate (0.2 g/kg) by gavage. The YD groups were given the corresponding concentration of YD (0.4 mL/20 g
body weight) by gavage. YD: Yiguanjian decoction.
A B C
D E F
Table 6 Comparison of protein expressions among groups
( xˉ ± s)
Group
Normal
Model
Bifendate
Middle-dose YD
Bax
1.00±0.14
0.73±0.12a
0.84±0.11b
1.22±0.05b
TNF-α
0.37±0.08
1.05±0.26a
0.38±0.15b
0.53±0.06b
MTH1
1.00±0.17
0.90±0.52a
0.95±0.25
1.02±0.28
Notes: the normal group and model group were given normal sa-
line daily for eight weeks. Bifendate group was administered Bi-
fendate by gavage. The YD groups were given the corresponding
concentration of YD by gavage. aP < 0.05, compared with nor-
mal group; bP < 0.05, compared with model group. TNF-α: tu-
mor necrosis factor-α; MTH1: MutT Homolog 1; YD: Yiguanji-
an decoction.
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el was prepared in this study, and the results of serum
ALT and AST and liver pathology suggested that the
model was established successfully. Experiment results
of SCGE showed that there was evident DNA damage
on the liver cells of model mice. The results suggest
that YD, a Chinese medicine for nourishing liver and
kidney, can improve the liver function and the degree
of liver fibrosis and inflammation in mice with im-
mune liver injury. Within a certain range, the effect of
the improvement of liver tissue inflammation and fi-
brosis degree will be enhanced with increasing dose.
The study suggests that the dose effect relationship is
remarkable.
The research suggested that YD can reduce the liver
cell DNA damage. The possible mechanisms may be
that YD can decrease the protein expression of TNF-α
and increase the mRNA expression of Bax and MTH1.
Con A-induced liver injury mice model, one of T-cells
mediated model, is a good simulation of the pathologi-
cal process of human viral hepatitis. Research suggested
the presence of DNA damage in Con A-induced acute
liver injury mice,16 and our test results confirmed that
Con A-induced chronic liver injury also existed DNA
damage. The reason may be related to increased secre-
tion of inflammatory cytokines such as TNF-α.
TNF-α caused DNA damage by the formation of 8-hy-
droxy-2 deoxyguanosine which was believed to be one
of the most abundant DNA lesions resulting from oxi-
dative stress.17 The study found that YD can significantly
inhibit the secretion of TNF-α then reduce the inflam-
matory environment of liver cells, thereby inhibiting
the hepatocyte DNA damage.
Acute inflammation can remove damaged tissue and re-
store the balance between organizational structures,
but chronic inflammation may cause malignant trans-
formation of cells. Many inflammatory mediators such
as TNF-α, interleukin (IL)-6 and IL-10 are confirmed
to participate in the initiation and progression of can-
cer, especially TNF-α plays an important role in the
early stage of tumor. High levels of TNF-α have effica-
cy in the treatment of cancer, but sustained low levels
of TNF-α leads to the development of cancer by pro-
ducing reactive oxygen species (ROS) and reactive ni-
trogen species (RNS). OH·and O2- in ROS can cause
DNA strand breaks then cause base deletion, oncogene
activation and inactivation of tumor suppressor genes
and ultimately may lead to tumorigenesis.18 Activation
of oncogenes and inactivation of tumor suppressor
genes are most frequently gene changes in the process
of tumor, abnormal expression of these genes affect the
biological behavior and clinical manifestations of tu-
mor.19 The biological function of oncogene Bcl-2 is to
increase the cells resistance to various apoptotic stimu-
li. Bcl-2 helps DNA damaged cells to survive and en-
ables aggregation of mutant product. Studies have
found that transgenic mice with overexpression of
Bcl-2 prone to cancer.20Tumor suppressor gene Bax can
inhibit Bcl-2 and promote cell apoptosis by forming
heterodimers with Bcl-2.21 Our research has found that
YD may increase the mRNA and protein expression of
Bax, thereby promote cell apoptosis so to prevent tu-
mor cells.
As the main genetic material of our body, the impor-
tance of DNA stability is self-evident. Oxidative dam-
age occurs when free radicals attack DNA, the body
can repair the damaged DNA through self repair mech-
anisms, so as to maintain the stability of DNA. There
are many ways to repair DNA oxidative damage in the
body like base-excision repair (BER), nucleotide exci-
sion repair, mismatch repair. BER is the major repair
mechanism that removes oxidized and alkylated. There
are about 100 species of enzymes participate in DNA
oxidative damage repair, 8-oxoguanine DNA glycosyl-
ase (OGG1) and MutT homolog 1 have been studied
the most.22 MTH1 protease can hydrolyze 8-oxoG in
the nucleotide pool, reduce the free 8-oxoG binding to
the DNA chain and reduce mutation caused by base A
and C counterpoint during DNA replication. The ab-
normal expression or defect of MTH1 gene is associat-
ed with cancers like colon cancer.23 The study found
that the mRNA expression of MTH1 in model group
decreased and increased in YD groups, indicated that
YD can promote the expression of MTH1. Whether
YD play a role in intervening OGG1 expression needs
further research.
Although the exact mechanism of HCC is unclear, the
Table 7 Comparison of mRNA expressions among groups ( xˉ
± s)
Group
Normal
Model
Bifendate
Middle-dose YD
n
6
6
6
6
Bax
1.40±0.53
0.89±0.31a
1.36±0.33b
1.16±0.56b
MTH1
0.66±0.22
0.54±0.34a
0.72±0.44b
0.71±0.68b
Notes: the normal group and model group were given normal sa-
line. Bifendate group was given Bifendate. The YD groups were
given the corresponding concentration of YD. aP < 0.05, com-
pared with normal group; bP < 0.05, compared with model
group. MTH1: MutT Homolog 1; YD: Yiguanjian decoction.
Table 8 Comparison of TNF-α expression among groups ( xˉ
± s)
Group
Normal
Model
Bifendate
Middle-dose YD
n
6
6
6
6
TNF-α (pg/mL)
375±50
564±25a
468±62b
472±87b
Notes: normal group and model group were given normal sa-
line. Bifendate group was given Bifendate. The YD groups were
given the corresponding concentration of YD. aP < 0.05, com-
pared with normal group; bP < 0.05, compared with model
group. TNF-α: tumor necrosis factor-α; YD: Yiguanjian decoc-
tion.
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risk increased with the degree of hepatitis.24 Tissue mi-
croenvironment plays an important role in the process
of hepatitis transforming into HCC. The inflammato-
ry microenvironment of chronic hepatitis can not only
increase the hepatocellular gene mutation, but also pro-
mote proliferation of genetic mutation cells.25 How to
restrain the DNA damage caused by inflammation of
liver cells, becomes the key to the prevention of hepati-
tis to liver cancer. In this study, SCGE assay was used
to detect the DNA damage in immune injury liver
cells, so as to observe the effect of YD inhibiting DNA
damage. The results suggested that YD can effectively
inhibit the DNA damage in immunological liver inju-
ry mice. It has instructive significance for the clinical
application of the drug to prevent hepatitis transform-
ing into HCC.
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